Daclatasvir
DAKLINZA
What it isA CYP3A4-metabolized HCV NS5A replication-complex inhibitor.
Why this oneGiven with sofosbuvir (with or without ribavirin) for pan-genotypic chronic hepatitis C, including decompensated cirrhosis.
What limits itNeeds dose adjustment with strong CYP3A inhibitors/inducers and can cause symptomatic bradycardia when combined with amiodarone.
⚠ BOXED WARNING
- HBV reactivation
Principal riskBoxed warning: risk of hepatitis B virus reactivation in HCV/HBV co-infected patients, sometimes fulminant.
Classes and tags
Clinical profile
Mechanism of action: Daclatasvir ballicule
